Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects

Journal of Clinical Pharmacology

Volumn 47, Issue 12, 2007, Pages 1508-1520

  Mousa, Shaker A ^a   Fuming Zhang, ^b   Aljada, Ahmad ^a   Chaturvedi, Seema ^a   Takieddin, Majde ^a   Haifeng Zhang, ^a,b   Lianli Chi, ^b   Cristina Castelli, M ^c   Friedman, Kristen ^c   Goldberg, Michael M ^c   Linhardt, Robert J ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c Emisphere Technologies   (United States)

Author keywords

Anticoagulants; Heparin composition; Oral heparin; Pharmacodynamics; Pharmacokinetics; Solid dosage form

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A ANTIBODY; BLOOD CLOTTING FACTOR 2A ANTIBODY; HEPARIN; N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; OCTANOIC ACID DERIVATIVE; SALCAPROZATE SODIUM; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOLECULAR WEIGHT; PHARMACODYNAMICS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THORAX PAIN;

ADMINISTRATION, ORAL; ADULT; CAPRYLATES; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; GELATIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 36148955381     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007307242     Document Type: Article

References (31)

1. Hirsh J., Warkentin TE, Raschke R., Granger C., Ohman EM, Dalen JE Heparin and low-molecular-weight-heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998 ; 114: 489S - 510S.
2. Jaques LB Heparins: anionic polyelectrolyte drugs. Pharmacol Rev. 1979 ; 31: 99-166.
3. Jin L., Abrahams JP, Skinner R., Petitou M., Pike RN, Carrell RW The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA. 1997 ; 94: 14683-14688.
4. Hull R., Raskob G., Pineo G., et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 ; 329: 1370-1376.
5. Koopman MM, Prandoni P., Piovella F., et al, for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996 ; 334: 682-687.
6. Klein W., Buchwald A., Hillis SE, et al, for the FRIC Investigators. Comparison of low-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997 ; 96: 61-68.
7. FRISC Study Group. Low-molecular weight heparin during instability in coronary artery disease. Lancet. 1996 ; 347: 561-568. 8. Kay R., Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995 ; 333: 1588-1593.
8. DalPozzo A., Acquasaliente M., Geron MR New heparin complexes active by intestinal absorption: I. Multiple ion pairs with basic organic compounds. Thromb Res. 1989 ; 56: 119-124.
9. Tidball CS, Lipman RI Enhancement of jejunal absorption of heparinoid sodium ethylenediamine-tetraacetate in the dog. Proc Soc Exp Biol Med. 1962 ; 111: 713-715.
10. Sue TK, Jaques LB, Yuen E. Effects of acidity, cations, and alcoholic fractionation on absorption of heparin from the gastrointestinal tract. Can J Physiol Pharmacol. 1976 ; 54: 613-618.
11. Engel RH, Rigg GJ Intestinal absorption of heparin facilitated by sulphate or sulfonated surfactant. Proc Soc Exp Bio Med. 1969 ; 13: 706-710.
12. Guarani S., Ferrari W. Olive oil-provoked, bile-dependent absorption of heparin from the gastrointestinal tract in rats. Pharm Res Commun. 1985 ; 17: 685-694.
13. Uno M., Nagasaki T., Hiroshi I., Sakuragawa N. Oral administration of liposomally-entrapped heparin to beagle dogs. Chem Pharm Bull. 1982 ; 30: 2245-2247.
14. Artmann C., Roding J., Ghyczy M., Pratzel HG Liposomes from soya phospholipids as percutaneous drug carriers. Arzneimittelforschung. 1990 ; 40: 1365-1368.
15. Jacques LB, Hiebert LM, Wice SM Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J Lab Clin Med. 1991 ; 117: 122-130.
16. Leone-Bay A., Santiago N., Achan D., et al. N-acylated α-amino acids as novel oral delivery agents for proteins. J Med Chem. 1995 ; 38: 4263-4269.
17. Leone-Bay A., Ho K-K., Agarwal R., et al. 4- [4-(2 hydroxybenzoyl) amino] phenyl butyric acid as a novel delivery agent for recombinant human growth hormone. J Med Chem. 1996 ; 39: 2571-2576.
18. Brayden D., Creed E., O'Connell A., Leipold H., Agarwal R., Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal installations and in caco-2 monolayers. Pharm Res. 1997 ; 14: 1772-1779.
19. Rivera T., Leone-Bay A., Paton D., Leipold H., Baughman R. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacology considerations. Pharm Res. 1997 ; 14: 1830-1834.
20. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J., Catella-Lawson F., FitzGerald GA Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans. Circulation. 1998 ; 98: 1610-1615.
21. Zhang F., Sun P., Muñoz E., et al. Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal Biochem. 2006 ; 353: 284-286.
22. Mousa SA, Linhardt R., Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006 ; 96: 816-821.
23. Mousa SA, Bozarth J., Barrett JS Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol. 2003 ; 43: 727-734.
24. Bitter T., Muir HM A modified uronic acid carbazole reaction. Anal Biochem. 1962 ; 4: 330-334.
25. Edens RE, Al-Hakim A., Weiler JM, Rethwisch DG, Fareed J., Linhardt RJ Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J Pharm Sci. 1992 ; 81: 823-827.
26. Thanawiroon C., Rice KG, Toida T., Linhardt RJ Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides. J Biol Chem. 2004 ; 279: 2608-2615.
27. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991 ; 78: 387-393.
28. Mousa SA, Kaiser B. Tissue factor pathway inhibitor in thrombosis and beyond: role of heparin. Drugs Future. 2004 ; 29: 751-762. 30. Hull RD, Raskob GE, Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 ; 315: 1109-1114.
29. Brill-Edwards P., Ginsberg JS, Johnston M., Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993 ; 119: 104-109.
30. Cohen M., Demers C., Gurfinkel EP, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997 ; 337: 447-452.
31. Lane DA, Adams L. Non-anti-coagulant uses of heparin. N Engl J Med. 1993 ; 329: 129-130.